Head-To-Head Review: Iterum Therapeutics (ITRM) & Its Peers

Iterum Therapeutics (NASDAQ:ITRM) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Iterum Therapeutics to similar businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, valuation, dividends and earnings.

Insider and Institutional Ownership

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Iterum Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Iterum Therapeutics Competitors	7792	13886	25778	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given Iterum Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics has less favorable growth aspects than its competitors.

Volatility and Risk

Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500. Comparatively, Iterum Therapeutics’ competitors have a beta of -4.04, meaning that their average stock price is 504% less volatile than the S&P 500.

Earnings & Valuation

This table compares Iterum Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	-$24.77 million	-0.04
Iterum Therapeutics Competitors	$3.54 billion	$3.17 billion	554.50

Iterum Therapeutics’ competitors have higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Iterum Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Iterum Therapeutics Competitors	-2,372.59%	-220.82%	-15.99%

Summary

Iterum Therapeutics competitors beat Iterum Therapeutics on 10 of the 13 factors compared.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.